VIGAMOX (moxifloxacin HCl ophthalmic solution) 0.5% is a 4th-generation fluoroquinolone anti-infective for topical ophthalmic use. To administer VIGAMOX solution, instill one drop in the affected eye(s) 3 times a day for 7 days. VIGAMOX solution is safe and effective for pediatric use in children aged 1 year and older
VIGAMOX solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
Aerobic Gram-positive microorganisms: Corynebacterium species*, Micrococcus luteus*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri*, Streptococcus pneumoniae, Streptococcus viridans group
Aerobic Gram-negative microorganisms: Acinetobacter Iwoffii*, Haemophilus influenzae, Haemophilus parainfluenzae*,
Other microorganisms: Chlamydia trachomatis
The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1% to 6% of patients.
VIGAMOX solution offers the broadest available coverage of fluoroquinolone eye drops with proven clinical efficacy against thirteen strains of susceptible microorganisms. VIGAMOX™ solution is BAC-free as a result of the inherent anti-bacterial and anti-fungal activity of the moxifloxacin formulation. VIGAMOX™ solution satisfies all the United States Pharmacopoeia requirements for preservative efficacy without the need for benzalkonium chloride, and, therefore, is referred to as "BAC-free."
As part of the United States Pharmacopoeia tests, VIGAMOX solution has been evaluated against a number of specified pathogens representative of a wide range of potential contaminants, including gram-positive and gram-negative bacteria, yeasts, and fungi. VIGAMOX solution not only meets, but exceeds all requirements of the United States Pharmacopoeia.